CJC-1295 NO DAC/IPAMORELIN 10mg

for: Growth Hormone; Seep; Energy and Lean Body Mass

CJC-1295 (No DAC) / Ipamorelin 10mg Blend is a specialized research formulation combining two mechanistically distinct growth hormone secretagogues. By utilizing CJC-1295 (Modified GRF 1-29) and Ipamorelin, this blend is engineered to investigate synergistic signaling within the growth hormone axis. Dragon Pharma provides this 10mg blend at a purity level of 99%+, specifically developed for in-vitro laboratory experiments and preclinical animal models.

Overview

In the field of endocrine research and cellular signaling, the combination of CJC-1295 (No DAC) and Ipamorelin has become a fundamental tool for exploring the regulation of Growth Hormone (GH). This blend functions by simultaneously targeting two different receptors in the pituitary gland: the GHRH receptor and the Ghrelin receptor (GHS-R1a). Dragon Pharma provides this 10mg blend (5mg/5mg) at a minimum purity of 99%, ensuring that researchers have access to a high-grade compound capable of producing reproducible data in complex biological systems.

As inquiry into tissue repair, metabolic regulation, and age-related physiological decline expands, the need for precise secretagogue blends has grown. This profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of the Dragon Pharma CJC-1295 / Ipamorelin 10mg Blend.

Molecular Characteristics and Chemical Profile

This blend consists of two primary peptides, each with a specific chemical signature designed to resist rapid proteolytic degradation while maintaining high receptor affinity.

• Chemical Identity (1): CJC-1295 (No DAC) / Modified GRF 1-29
• Chemical Identity (2): Ipamorelin
• Molecular Formula:  C165H269N47O46 (CJC-1295) | C38H49N9O5 (Ipamorelin)
• Molecular Weight: 3367.9 g/mol (CJC-1295) | 711.9 g/mol (Ipamorelin)
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

This peptide blend is utilized in various scientific investigative domains, including:

• Endocrine Pulsatility: Mapping the frequency and amplitude of growth hormone pulses.
• Synergistic Signaling: Investigating the cross-talk between Gs-protein and Gq-protein signaling pathways.
• Cellular Metabolism: Assessing the modulation of the IGF-1 axis and its impact on protein synthesis.
• Sleep Architecture: Studying the impact of secretagogues on slow-wave sleep cycles in animal models.
• Tissue Regeneration: Evaluating potential mechanisms for wound healing and connective tissue repair.

Pathway and Mechanistic Context

The core value of this blend is its dual-pathway activation. While many secretagogues act in isolation, this formulation mimics the natural physiological environment where multiple triggers coordinate GH release.

The GHRHR and GHS-R1a Axis

1. CJC-1295 (GHRH Analog): Targets the GHRH receptors on the pituitary somatotrophs. It activates the cAMP/PKA-mediated pathway, which is essential for the synthesis of new growth hormone.
2. Ipamorelin (Ghrelin Mimetic): Binds to the GHS-R1a receptor. This triggers intracellular calcium mobilization through the PLC pathway, which facilitates the release (secretion) of growth hormone.

Key Mechanistic Shifts:

• Enhanced Secretion: The combination is researched for its ability to produce a larger GH release than either peptide alone, without the significant prolactin or cortisol spikes associated with older secretagogues.
• Pulsatile Integrity: Unlike "DAC" versions, the "No DAC" blend allows for the study of pulsatile release, which more closely resembles natural endocrine rhythms.

Primary Research Applications

1. Metabolic and IGF-1 Research

Researchers utilize this blend to investigate the downstream modulation of Insulin-like Growth Factor 1 (IGF-1). Because this axis regulates lean mass and lipid metabolism, it is a primary area of focus for studies involving metabolic efficiency.

2. Tissue Repair and Collagen Synthesis

In preclinical models, the secretagogue blend is used to observe the rate of collagen synthesis and bone mineral density changes. This makes it a vital tool for labs exploring the reversal of age-related tissue frailty.

3. Sleep and Circadian Rhythm Studies

Ipamorelin's high selectivity makes it a candidate for studying the relationship between the growth hormone axis and deep sleep phases. Researchers evaluate how GHRH analogs influence the central nervous system's regulation of recovery during sleep.

Form and Analytical Testing

At Dragon Pharma, scientific accuracy is maintained through a rigorous manufacturing and verification process.

• Lyophilization for Stability: The blend is supplied in a freeze-dried form, preserving the molecular structure against temperature fluctuations during transit.
• Rigorous Analytical Verification: Every batch undergoes High-Performance Liquid Chromatography (HPLC) to ensure concentration accuracy and Mass Spectrometry (MS) to confirm the exact molecular signatures of both CJC-1295 and Ipamorelin

Product Usage Disclaimer: This product is intended for laboratory and in-vitro research use only. It is not approved for human or veterinary application. Must be handled by qualified professionals. Not for drug, food, or cosmetic purposes. Misuse or misbranding is strictly prohibited.